• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

mRNA BNT162b2 疫苗接种 6 个月后大型健康维护组织中患者的有效性,以色列。

Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel.

出版信息

Emerg Infect Dis. 2022 Feb;28(2):338-346. doi: 10.3201/eid2802.211834. Epub 2021 Dec 14.

DOI:10.3201/eid2802.211834
PMID:34906291
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8798683/
Abstract

Israel experienced a new wave of coronavirus disease during June 2021, six months after implementing a national vaccination campaign. We conducted 3 discrete analyses using data from a large health maintenance organization in Israel to determine whether IgG levels of fully vaccinated persons decrease over time, describe the relationship between IgG titer and subsequent PCR-confirmed infection, and compare PCR-confirmed infection rates by period of vaccination. Mean IgG levels steadily decreased over the 6-month period in the total tested population and in all age groups. An inverse relationship was found between IgG titer and subsequent PCR-positive infection. Persons vaccinated during the first 2 months of the campaign were more likely to become infected than those subsequently vaccinated. The vaccinated group >60 years of age had lower initial IgG levels and were at greater risk for infection. The findings support the decision to add a booster vaccine for persons >60 years of age.

摘要

2021 年 6 月,以色列在开展全国性疫苗接种运动六个月后,迎来了新一轮的冠状病毒疾病。我们使用以色列一家大型健康维护组织的数据进行了 3 项独立分析,以确定完全接种疫苗的人的 IgG 水平是否会随时间下降,描述 IgG 滴度与随后 PCR 确诊感染之间的关系,并比较按接种时间划分的 PCR 确诊感染率。在整个检测人群和所有年龄组中,IgG 水平在 6 个月的时间里呈稳步下降趋势。发现 IgG 滴度与随后的 PCR 阳性感染呈负相关。在疫苗接种运动的前两个月接种疫苗的人比随后接种疫苗的人更容易感染。60 岁以上的接种组初始 IgG 水平较低,感染风险更高。这些发现支持为 60 岁以上人群接种加强疫苗的决定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3db/8798683/f6bb346728da/21-1834-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3db/8798683/c4eec384544b/21-1834-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3db/8798683/f6bb346728da/21-1834-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3db/8798683/c4eec384544b/21-1834-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3db/8798683/f6bb346728da/21-1834-F2.jpg

相似文献

1
Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel.mRNA BNT162b2 疫苗接种 6 个月后大型健康维护组织中患者的有效性,以色列。
Emerg Infect Dis. 2022 Feb;28(2):338-346. doi: 10.3201/eid2802.211834. Epub 2021 Dec 14.
2
Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.BNT162b2 疫苗接种与孕妇感染 SARS-CoV-2 的关联。
JAMA. 2021 Aug 24;326(8):728-735. doi: 10.1001/jama.2021.11035.
3
Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain.mRNA 疫苗对西班牙长期护理机构中严重急性呼吸综合征冠状病毒 2 有效性的直接和间接影响
Emerg Infect Dis. 2021 Oct;27(10):2595-2603. doi: 10.3201/eid2710.211184. Epub 2021 Jul 27.
4
Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.BNT162b2 mRNA COVID-19 疫苗的抗体反应动力学:7 个月随访研究。
Medicina (Kaunas). 2021 Dec 5;57(12):1330. doi: 10.3390/medicina57121330.
5
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.接种 BNT162b2 疫苗和加强针后,Delta 变异株 SARS-CoV-2 突破感染的病毒载量。
Nat Med. 2021 Dec;27(12):2108-2110. doi: 10.1038/s41591-021-01575-4. Epub 2021 Nov 2.
6
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.BNT162b2 新冠病毒疫苗与体液免疫应答及动力学的相关性:医护人员前瞻性、单中心、纵向队列研究。
Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2.
7
BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel.BNT162b2 疫苗突破性感染:以色列 152 名完全接种疫苗的住院 COVID-19 患者的临床特征。
Clin Microbiol Infect. 2021 Nov;27(11):1652-1657. doi: 10.1016/j.cmi.2021.06.036. Epub 2021 Jul 7.
8
Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021.2021 年以色列 SARS-CoV-2 德尔塔变异株感染爆发期间 BNT162b2 疫苗在青少年中的有效性。
Emerg Infect Dis. 2021 Nov;27(11):2919-2922. doi: 10.3201/eid2711.211886. Epub 2021 Sep 27.
9
Humoral immune response after different SARS-CoV-2 vaccination regimens.不同 SARS-CoV-2 疫苗接种方案后的体液免疫应答。
BMC Med. 2022 Jan 21;20(1):31. doi: 10.1186/s12916-021-02231-x.
10
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.BNT162b2 和 mRNA-1273 两种 SARS-CoV-2 疫苗接种后的 IgG 抗体反应差异。
Microbiol Spectr. 2021 Dec 22;9(3):e0116221. doi: 10.1128/Spectrum.01162-21. Epub 2021 Nov 10.

引用本文的文献

1
SARS-CoV-2 Humoral Immunity Persists Following Rituximab Therapy.利妥昔单抗治疗后,严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)体液免疫依然存在。
Vaccines (Basel). 2023 Dec 18;11(12):1864. doi: 10.3390/vaccines11121864.
2
Risk Stratification Model for Severe COVID-19 Disease: A Retrospective Cohort Study.重症新型冠状病毒肺炎疾病风险分层模型:一项回顾性队列研究。
Biomedicines. 2023 Mar 2;11(3):767. doi: 10.3390/biomedicines11030767.
3
Effect of Vaccination Time Intervals on SARS-COV-2 Omicron Variant Strain Infection in Guangzhou: A Real-World Matched Case-Control Study.

本文引用的文献

1
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.辉瑞-BioNTech 信使核糖核酸新冠病毒疫苗 6 个月的安全性和有效性
N Engl J Med. 2021 Nov 4;385(19):1761-1773. doi: 10.1056/NEJMoa2110345. Epub 2021 Sep 15.
2
Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination.BNT162b2 疫苗接种后 SARS-CoV-2 抗-S IgG 的动力学。
Vaccine. 2021 Sep 7;39(38):5337-5340. doi: 10.1016/j.vaccine.2021.08.025. Epub 2021 Aug 11.
3
Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.
接种时间间隔对广州SARS-CoV-2奥密克戎变异株感染的影响:一项真实世界匹配病例对照研究
Vaccines (Basel). 2022 Nov 1;10(11):1855. doi: 10.3390/vaccines10111855.
4
Preventive Behaviors and Information Sources during COVID-19 Pandemic: A Cross-Sectional Study in Japan.《COVID-19 大流行期间的预防行为和信息来源:日本的一项横断面研究》。
Int J Environ Res Public Health. 2022 Nov 4;19(21):14511. doi: 10.3390/ijerph192114511.
5
Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK).新型冠状病毒2疫苗抗体反应的决定因素:基于人群的纵向研究(英国COVIDENCE)
Vaccines (Basel). 2022 Sep 23;10(10):1601. doi: 10.3390/vaccines10101601.
6
A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?对 COVID-19 大流行第一年疫苗接种情况的快速范围综述:我们是需要更多疫苗还是更多时间?
Medicine (Baltimore). 2022 Sep 16;101(37):e30609. doi: 10.1097/MD.0000000000030609.
7
Current clinical status of new COVID-19 vaccines and immunotherapy.新型 COVID-19 疫苗和免疫疗法的当前临床状况。
Environ Sci Pollut Res Int. 2022 Oct;29(47):70772-70807. doi: 10.1007/s11356-022-22661-1. Epub 2022 Sep 5.
8
Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.CoronaVac 和 BNT162b2 异源初免-加强免疫的体液免疫应答特征。
Vaccine. 2022 Aug 19;40(35):5189-5196. doi: 10.1016/j.vaccine.2022.07.023. Epub 2022 Jul 27.
9
Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccines-Effectiveness in Delta Variant Breakthrough Infections.两剂抗 SARS-CoV-2 疫苗接种后医护人员体液免疫反应的随访 - Delta 变异突破感染的有效性。
Viruses. 2022 Jun 24;14(7):1385. doi: 10.3390/v14071385.
10
Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs.同源加强 COVID-19 疫苗接种在卫生保健工作者中引发了强烈的免疫反应。
Diagn Microbiol Infect Dis. 2022 Oct;104(2):115758. doi: 10.1016/j.diagmicrobio.2022.115758. Epub 2022 Jul 1.
英国普通人群中 45965 名成年人对 SARS-CoV-2 疫苗的抗体反应。
Nat Microbiol. 2021 Sep;6(9):1140-1149. doi: 10.1038/s41564-021-00947-3. Epub 2021 Jul 21.
4
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2(德尔塔)变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
5
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.COVID-19 mRNA 疫苗诱导针对三种 SARS-CoV-2 变体的抗体反应。
Nat Commun. 2021 Jun 28;12(1):3991. doi: 10.1038/s41467-021-24285-4.
6
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
7
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.以色列全国疫苗接种运动后,mRNA BNT162b2疫苗对SARS-CoV-2感染及COVID-19病例、住院和死亡的影响与效果:一项利用国家监测数据的观察性研究
Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5.
8
COVID-19 vaccine impact in Israel and a way out of the pandemic.新冠疫苗在以色列的影响以及走出疫情大流行的途径。
Lancet. 2021 May 15;397(10287):1783-1785. doi: 10.1016/S0140-6736(21)01018-7. Epub 2021 May 5.
9
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
10
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection.新型冠状病毒血清阳性抗体检测与未来感染风险的关系。
JAMA Intern Med. 2021 May 1;181(5):672-679. doi: 10.1001/jamainternmed.2021.0366.